search: results update below


browse funds: selections are stored



recently rated:

Rated by 7
3.1
 

top rated funds:

Rated by 12
4.1

Rated by 12
4.0
 

Rated by 11
4.0
 

Rated by 15
4.0

Rated by 41
3.9

Rated by 11
3.8

Rated by 44
3.8

Rated by 106
3.8

Rated by 32
3.8

Rated by 32
3.8

Rated by 64
3.7

Rated by 23
3.7

Rated by 27
3.7

Rated by 11
3.6

Rated by 18
3.6

Rated by 10
3.6
 

Rated by 62
3.6

Rated by 21
3.5

Rated by 12
3.5
 

Rated by 30
3.5

Rated by 28
3.4

Rated by 19
3.4

Rated by 14
3.4
 

Rated by 49
3.4
 

Rated by 16
3.4
 

Rated by 10
3.4

Rated by 13
3.4

Rated by 16
3.4

Rated by 60
3.4

Rated by 17
3.4

Please take a moment and make a financial contribution to TheFunded. If we have helped you, help us with resources to further grow the both the site and our entrepreneur training program, The Founder Institute.

MPM Capital  CERTIFIED

Firm Rating:

Rated 3.4 / 5.0 by 3
Track
Record
4.0
Operating
Competence
3.5
Pitching
Efficiency
3.5
Favorable
Deal Terms
3.3
Execution
Assistance
2.7

Firm Homepage:

FIRM OVERVIEW: Very Large Private VC founded in 1997 based out of Boston, USA (US East)

FIRM DESCRIPTION: Focused on private, entrepreneurial companies, the BioVentures funds are designed to finance, structure and support those companies MPM believes will become industry leaders. Their charters are to invest across the spectrum of opportunities from financing start-ups to leading private equity financings of public companies. MPM's venture capital resources reflect the increasing specialization and complexity of the fast evolving healthcare space, with a team that has proven track records in venture capital, biotechnology and pharmaceutical research, business development, marketing and sales and the general management of leading industry companies. The MPM BioVentures team is headquartered at two locations - Boston and San Francisco - both centers of innovation where we can monitor technical breakthroughs and swiftly respond to market opportunities. The four MPM BioVentures funds comprising the Firm's venture capital activities, BioVentures I, BioVEntures II, BioVentures III, and most recently, BioVentures IV today represent over $2.5 billion in committed capital. All four funds are designed to invest primarily in the U.S., and secondarily in Europe and Asia, with investments that range from $5 - $60 million per portfolio opportunity.

TEAM MEMBERS: Ansbert Gadicke, Ashley Dombkowski, Jim Scopa, John Vander Vort, Kurt von Emster, Luke Evnin, Steven St. Peter, Vaughn Kailian, William Greene,